Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
This article was originally published in The Pink Sheet Daily
Executive Summary
The NDA will be based on either a 224-patient myeloma study or a 241-patient CLL study. Genta says that it has received helpful feedback from FDA since withdrawing a Genasense NDA for melanoma.